Načítá se...
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
Postmenopausal women have an increased risk of osteopenia and osteoporosis due to loss of the bone-protective effects of estrogen. Disease-related processes may also contribute to the risk of bone loss in postmenopausal women with breast cancer. One of the most common and severe safety issues associ...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2012
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3846762/ https://ncbi.nlm.nih.gov/pubmed/24367197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S29432 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|